Tasigna (nilotinib) — United Healthcare

Initial criteria

• Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tasigna therapy

Approval duration

12 months